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Figure S1. Related to Figure 1. Effects of GABA-Transaminase inhibition in obese (A-H) and lean (I-P) 
male mice. (A-H) Glucose homeostasis in obese male mice treated with the GABA-Transaminase inhibitor 
ethanolamine-O-sulfate (EOS; 3 g/L in drinking water). EOS effects on serum insulin (A) glucose (B), and 
glucose:insulin ratio (C) pre-treatment and after 4 days of treatment. Oral glucose tolerance (OGTT; D) 
OGTT area under the curve (OGTT AUC; E), and oral glucose stimulated insulin (F) pre-treatment and 
after 3 days of treatment. Insulin tolerance (ITT; G) and ITT AUC (H) pre-treatment, on day 4 of treatment 
(EOS), and after a 2-week washout period. (I-P) Glucose homeostasis in lean male mice treated with 
GABA-Transaminase inhibitors EOS or vigabatrin (8 mg/day), or phosphate buffered saline (PBS; control). 
Serum insulin (I), glucose (J), and glucose:insulin ratio (K) on treatment day 4. Oral glucose tolerance 
(OGTT; L), OGTT AUC (M), and oral glucose stimulated serum insulin (N) on treatment day 3. Insulin 
tolerance (ITT; O) and ITT AUC (P) on treatment day 4. NS = non-significant. a,b Bars that do not share a 
common letter differ significantly (P < 0.05; number below bar denotes n per group). All data are presented 
as mean ± SEM. 
  
 
Figure S2. Related to Figure 2. Chronic hepatic GABA-Transaminase knockdown improves obesity 
induced metabolic dysfunction (A-F) and is dependent on an intact hepatic vagal nerve (G-P). (A-F) High 
fat diet-induced obese mice were treated for 4 weeks with a GABA-T targeted or scramble control antisense 
oligonucleotide (ASO; 12.5 mg/kg IP twice weekly). Release of GABA (µmol/mg DNA) from hepatic 
slices (A). Body weight during treatment (B). Basal serum insulin (C), glucose (D), and glucose:insulin 
ratio (E) pre-treatment and after 4 weeks of treatment. Serum glucagon (F) after 4 weeks of treatment. (G-
P) Diet-induced obese hepatic vagotomized and sham operated mice were treated with a GABA-T targeted 
ASO (12.5 mg/kg IP twice weekly) for 4 weeks. Body weight during treatment (G). Basal serum insulin 
(H), glucose (I), and glucose:insulin ratio (J) pre-treatment and after 4 weeks of treatment. Serum glucagon 
(K), oral glucose tolerance (OGTT; L), OGTT area under the curve (AUC; M), oral glucose stimulated 
serum insulin (N), insulin tolerance (ITT; O), and ITT AUC (P) after 4 weeks of treatment. Number below 





Figure S3. Related to Figure 2. Glucose homeostasis in lean mice treated with the scramble control 
antisense oligonucleotide (ASO), or 1 of 2 GABA-Transaminase (GABA-T) targeted ASO sequences 
(GABA-T or GABA-T 2; 12.5 mg/kg IP twice weekly) for 4 weeks. Hepatic GABA-T mRNA expression 
after 1, 2, and 4 weeks of ASO injections (A). GABA-T mRNA expression in liver, whole-brain, and 
pancreas after 4 weeks of ASO injections (B). Body weight during treatment (C). Basal serum insulin (D), 
glucose (E), and glucose:insulin ratio (F) pre-treatment and after 1, 2, 3, and 4 weeks of treatment. Oral 
glucose tolerance (OGTT; G), OGTT area under the curve (AUC; H), oral glucose stimulated serum 
insulin (I), insulin tolerance (ITT; J), and ITT AUC (K). a,b,c Bars that do not share a common letter differ 
significantly (P < 0.05). Number below bar denotes n per group. NS = non-significant. All data are 
presented as mean ± SEM.  
 
Figure S4. Related to Figure 1. GABA-Transaminase inhibition improves glucose homeostasis in sham but 
not vagotomy mice. HFD induced sham operated and hepatic vagotomized mice were treated with the 
GABA-Transaminase inhibitor ethanolamine-O-sulfate (EOS) (8mg/day) for 5 days. Body weight during 
treatment (A). Basal serum insulin (B), glucose (C), and glucose:insulin ratio (D) pre-treatment, on 
treatment day 5, and after a 2-week washout. Oral glucose tolerance in sham mice (OGTT; E), oral glucose 
tolerance in vagotomized mice (F) OGTT area under the curve (AUC; G), and glucose stimulated serum 
insulin (H) pre-treatment, on treatment day 4, and after a 2-week washout. Insulin tolerance in sham mice 
(ITT; I) and vagotomized mice (J), and ITT AUC (K) at pre-treatment, on treatment day 5, and after a 2-
week washout. NS = non-significant. a,b Bars that do not share a common letter differ significantly within 




Figure S5.  Related to Figure 2. Pair-feeding to equal the caloric restriction that results from GABA-T 
knockdown does not explain the metabolic improvements associated with GABA-T ASO treatment.  Pair 
feeding did not affect body mass (A), decreased cumulative food intake (FI) by 13% relative to ad libitum 
fed controls (B), and had no effect of change in glucose during an oral glucose tolerance test (C and D), 
insulin sensitivity (E and F), or body mass, fat mass or lean mass loss (G). Number below bar denotes n per 
group. NS = non-significant. All data are presented as mean ± SEM.  
 
Figure S6. Related to Figure 4. Hepatic GABA-Transaminase knockdown does not affect fast induced 
refeeding or leptin sensitivity. Refeeding after a 16-hour fast in chow fed lean (A) and diet induced obese 
(B) mice after 4 weeks of GABA-T targeted or scramble control ASO injections (12.5 mg/kg IP twice 
weekly). Hypothalamic fasted mRNA expression of GABA-T, neuropeptide Y (NPY), agouti related 
peptide (AgRP), and pro-opiomelanocortin (POMC) after 7 weeks of ASO injections. Central GABA-T 
mRNA expression after 4 weeks of ASO injections (D). The effect of leptin (2 mg/kg IP single injection at 
6am) on food intake (E) and body weight change (F) in obese control and GABA-T knockdown mice, and 
food intake (G) and body weight change (H) in lean mice. Number below bar denotes n per group. NS = 





Figure S7. Related to Figure 5. Hepatic GABA-T knockdown does not alter energy expenditure in obesity. 
Energy expenditure, respiratory exchange ratio, and activity level were assessed by Comprehensive Lab 
Animal Monitoring System (CLAMS) at the UCDavis Mouse Metabolic Phenotyping Center in diet-
induced obese mice after 0, 1, and 4 weeks of GABA-T targeted or scramble control antisense 
oligonucleotide treatment (ASO; 12.5 mg/kg IP twice weekly). Energy expenditure during the light cycle 
(A), dark cycle (B), and over 24 hours (C). Respiratory exchange ratio (RER) during the light cycle (D) and 
dark cycle (E). 24 hour water intake (F). 24 hour activity along the horizontal X axis (XTOT; G), total 
ambulatory movement (XAMB; H), and vertical Z axis (ZTOT; I). NS = non-significant. All data are 
presented as mean ± SEM. 
  
 
Figure S8. Related to Figure 4. Hepatic vagotomy decreases light cycle food intake on HFD, while GABA-
Transaminase knockdown normalizes sham mice food intake to vagotomy mice. Cumulative food intake 
and body weight in diet-induced obese sham operated and hepatic vagotomized mice during 1 week of 
baseline feeding (A-B) and during 2 weeks of GABA-T targeted antisense oligonucleotide injections (ASO; 
12.5 mg/kg IP twice weekly; C-F). Cumulative basal light cycle, dark cycle, and daily food intake (A) and 
cumulative body weight change (B). Cumulative ASO light cycle, dark cycle, and daily food intake (C) and 
cumulative body weight change (D). Weekly cumulative food intake (E) and cumulative body weight 
change (F). All data are presented as mean ± SEM. 
  
 
Figure S9. Related to Figures 1 and 2. Insulin tolerance tests (ITT) presented as raw glucose values. ITT 
on day 4 of EOS or Vigabatrin (8 mg/day), or PBS treatment in obese mice (A). ITT pre-treatment, on day 
4 of oral EOS (3 g/L in drinking water) treatment, and after a 2-week washout period (B). ITT on day 4 of 
EOS or Vigabatrin (8mg/day), or PBS treatment in lean mice (C). ITT in obese mice after 1 week of control 
or GABA-T antisense oligonucleotide (ASO) treatment (D). ITT in lean mice after 4 weeks of control, 
GABA-T, or GABA-T 2 ASO treatment (E). ITT in sham (F) and vagotomized mice (G) at pre-treatment, 
on day 5 of EOS (8 mg/day) treatment, and after a 2-week washout period. ITT in obese sham and 
vagotomized mice after 4 weeks of GABA-T ASO treatment (H). a,b,c data points that do not share a common 
letter differ significantly (P < 0.05) within a timepoint. † Denotes the data point is not significantly different 
from time 0 for that group (P > 0.05). Unless indicated, all other timepoints are significantly different from 
time 0 within a group of mice. * Denotes significance between groups specified in the panel within a 
timepoint. All data are presented as mean ± SEM.  
  
Supplemental Tables and Legends 
 
Table S1. Metabolic characteristics of the study subjects (n=19). Related to Figure 6.  
 Mean ± SEM Range 
Body mass index (kg/m2) 45.1 ± 1.3 35.9 - 55.6 
Intrahepatic triglyceride content (%) 11.4 ± 1.9 2.7 - 28.0 
Glucose (mg/dL) 97 ± 2 81 - 121 
Insulin (μU/mL) 24.1 ± 1.7 13.1 - 46.5 
Glucose infusion rate during insulin infusion 
(μmol/kg FFM/min) 
36.0 ± 3.0 15.2 - 60.8 
Glucose Rd during insulin infusion (% increase) 131 ± 19 30 - 355 
FFM, fat free mass; Glucose Rd, glucose disposal rate. 
 
Table S2. Related to Figure 6. Regression coefficient estimates showing 
the association between hepatic mRNA expression of genes involved in 
GABA production (ABAT) and GABA transport (SLC6A6, SLC6A8, 
SLC6A12, and SLC6A13) and basal plasma insulin concentration 
(μU/mL) or hepatic insulin sensitivity index (HISI). 







CI P- Value 
Intercept -52.50 40.31 -143.67 38.68 0.2251 
IHTG (%) 0.30 0.14 -0.01 0.62 0.0577 
ABAT 18.14 5.28 6.19 30.09 0.0075 
SLC6A1
2 -14.71 4.29 -24.41 -5.01 0.0075 
SLC6A1
3 1.90 3.14 -5.19 8.99 0.5595 
SLC6A6 3.02 2.40 -2.41 8.45 0.2395 









CI P- Value 
Intercept 16.41 7.23 0.06 32.76 0.0493 
IHTG (%) -0.05 0.03 -0.11 0.00 0.0674 
ABAT -2.94 0.95 -5.08 -0.80 0.0127 
SLC6A1
2 2.38 0.77 0.64 4.12 0.0127 
SLC6A1
3 -0.71 0.56 -1.98 0.56 0.2379 
SLC6A6 -0.21 0.43 -1.19 0.76 0.6340 
SLC6A8 0.17 0.26 -0.43 0.76 0.5416 
7
Table S3. Related to Figure 6. Single Nucleotide Polymorphisms (SNPs) in the promoter of the ABAT gene, which encodes for GABA 
transaminase, are associated with a decreased odds ratio (OR) for type 2 diabetes (T2D; Source: knowledge portal diabetes database).  MAF – 
minor allele frequency. 
ABAT - T2D Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value 
Effec
t OR MAF 
16_8743360_C_




4 Promotor-intergenic DIAGRAM 1000G GWAS 0.0036 ↓ 0.852 0.005-0.01 
16_8758576_C_
G rs12933032 Promotor-intergenic 
UK Biobank T2D GWAS (DIAMANTE-Europeans Sept 
2018) 0.028 ↓ 0.962 0.1 
     
  
Table S4. Related to Figure 6. Single Nucleotide Polymorphisms (SNPs) that result in missense mutations in GABA transporters are associated 
with BMI (Source: knowledge portal diabetes database).  MAF – minor allele frequency. 
SLC6A12 - BMI Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect Effect Size MAF 
12_313824_G_A rs199521597 
Missense:  Replaces 
Alanine with Valine 
GIANT 2018 BMI, Height exome 




Missense:  Replaces 
Cysteine with Arginine GIANT UK Biobank GWAS 0.0031 ↑ 0.0053 0.426 
12_309921_T_C rs143648821 
Missense:  Replaces 
Isoleucine with Valine FUSION exome chip analysis 0.00316 ↑ 0.815 0.00105 
12_309864_C_T rs11061915 
Missense: Replaces Valine 
with Isoleucine 13K exome sequence analysis 0.00623 ↑ 0.299 0.00354 
12_300248_C_G,T rs147574089 
Missense: Replaces 
Glutamate with Glutamine 
GIANT 2018 BMI, Height exome 
chip analysis: Hispanics 0.0081 ↑ 0.65 NaN 
12_300298_C_T rs537332809 
Missense:  Replaces 
Arginine with Glutamine 13K exome sequence analysis 0.0141 ↑ 1.09 0.000381 
  
SLC6A6 - BMI Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect Effect Size MAF 
3_14523209_G_A rs141254266 
Missense: Replaces Valine 




Missense: Replaces Valine 
with Isoleucine 
GIANT 2018 BMI, Height exome 





Arginine with Histadine 
GIANT 2018 BMI, Height exome 




SLC6A13 - BMI Associated SNPs 
Variant ID dbSNP ID Predicted Impact Study P-value Effect Effect Size MAF 
12_332337_C_T rs202217743 
Missense: Replaces Valine 
with Leucine, or Methionine 
FinnMetSeq exome sequence 
analysis 0.0123 ↑ 1.26 0.0001 
12_331781_C_T,G rs147388541 
Missense: Replaces 
Aspartate with Histadine, or 
Asparginine 
GIANT 2018 BMI, Height exome 





Glutamate with Lysine 
GIANT 2018 BMI, Height exome 




Missense: Replaces Glycine 
with Serine  13K exome sequence analysis 0.0341 ↑ 0.489 
0.00001-
0.00055 
